Sevelamer carbonate Winthrop is a medicine used to control hyperphosphataemia (high blood phosphate levels) in: * adult patients on dialysis (a technique to remove unwanted substances from the blood); * adults and children from 6 years of age with chronic (long term) kidney disease. Sevelamer carbonate Winthrop should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease. It contains the active substance sevelamer carbonate.
Therapeutic Indication
Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus \> 1\.78 mmol/L. Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25\-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Therapeutic Area (MeSH)
ATC Code
V03AE02
ATC Item
N/A
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
EMA Name
Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
Medicine Name
Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
Aliases
N/ANo risk management plan link.
